business / news / / CNBC
Merck on Thursday reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.
Merck narrowed its 2026 revenue guidance to $65.8-$67 billion, raising the lower end by $0.3 billion.
KEY POINTS
- A $3.62 per share acquisition charge from Cidara Therapeutics led to Merck's quarterly net loss.
- New injectable Keytruda formulation achieved $128 million in sales, aiding future post-patent strategy.
- Winrevair sales rose 88% to $525 million, significantly surpassing analyst estimates due to market expansion.
- Gardasil vaccine sales fell 19% amid halted China shipments and lower demand in Japan and the U.S.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →